These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36610499)

  • 1. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
    Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy, Acceptability, and Application: Fecal Immunochemical Tests for Early Detection of Advanced Neoplasia in Colonoscopy-Based Surveillance.
    Wassie MM; Dix M; Laven-Law G; Bulamu N; Cock C; Bampton P; Fraser RJ; Winter JM; Young GP; Symonds EL
    Dig Dis Sci; 2024 Jul; 69(7):2621-2630. PubMed ID: 38753241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing colorectal cancer screening in high-risk population through fecal immunochemical test surveillance: Results from a surveillance program.
    Qin H; Zhang M; Zhang G; Zhao L; Zhang H; Zhang W; Wang Y; Zhang X; Xie L; Qian B
    Cancer Med; 2024 Oct; 13(20):e70145. PubMed ID: 39428708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy.
    Berwald G; Young GP; Cock C; Bampton P; Fraser R; Symonds EL
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):878-885.e2. PubMed ID: 37743036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal immunochemical test mitigates risk of delayed colonoscopy in people with elevated risk of colorectal neoplasia.
    Wassie MM; Young GP; Cock C; Bampton P; Winter JM; Simpson K; Saluja H; Chuang A; Fraser RJ; Symonds EL
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1067-1075. PubMed ID: 35261071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study.
    Terhaar sive Droste JS; van Turenhout ST; Oort FA; van der Hulst RW; Steeman VA; Coblijn U; van der Eem L; Duijkers R; Bouman AA; Meijer GA; Depla AC; Scholten P; Loffeld RJ; Coupé VM; Mulder CJ
    BMC Gastroenterol; 2012 Jul; 12():94. PubMed ID: 22828158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of adenomatous polyposis in a fecal immunochemical test-based colorectal cancer screening program and risk of advanced neoplasia during follow-up.
    Carballal S; Sánchez A; Moreira L; Cuellar-Monterrubio JE; Bernuy J; Daca M; Ortiz O; Ocaña T; Rivero-Sánchez L; Jung G; Serradesanferm A; Pozo A; Grau J; Torá I; Zaffalon D; Castells A; Pellisé M; Balaguer F;
    Endoscopy; 2022 Jul; 54(7):688-697. PubMed ID: 34607378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer.
    Baldacchini F; Bucchi L; Giuliani O; Mancini S; Ravaioli A; Vattiato R; Giorgi Rossi P; Campari C; Canuti D; Di Felice E; Mezzetti F; Sassoli de Bianchi P; Ferretti S; Falcini F;
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2361-2369. PubMed ID: 32827723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal immunochemical testing results and characteristics of colonic lesions.
    van Doorn SC; Stegeman I; Stroobants AK; Mundt MW; de Wijkerslooth TR; Fockens P; Kuipers EJ; Bossuyt PM; Dekker E
    Endoscopy; 2015 Nov; 47(11):1011-7. PubMed ID: 26126163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
    Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
    Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.